secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001193125-22-211760
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal on track for MAESTRO-NASH topline data in Q4 2022; Q2 cash $211.8M
---------------------------------------------------------------------------

- Topline data from Phase 3 MAESTRO-NASH biopsy study expected in Q4 2022; NDA filing planned for H1 2023.
- Cash, cash equivalents and marketable securities of $211.8M as of June 30, 2022, down from $270.3M at Dec 31, 2021.
- Q2 2022 operating expenses $70.3M (R&D $58.5M, G&A $11.8M) vs $61.7M in Q2 2021.
- Expanded market development activities; payer education sessions covering >80% of U.S. branded prescriptions.
- Plans to initiate MAESTRO-NASH Outcomes study in ~700 early NASH cirrhosis patients for full approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312522211760/0001193125-22-211760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312522211760/d370174d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-211760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer